TNGX Q1 2021 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+35.6% YoY

Gross Profit

$6M93.0% margin

Operating Income

-$12M-189.2% margin

Net Income

-$12M-189.6% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

-30.1%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$950,000

Balance Sheet

Total Assets

$224M

Total Liabilities

$166M

Stockholders' Equity

$58M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$5M	+35.6%
Gross Profit	$6M	-$6M	+197.2%
Operating Income	-$12M	-$8M	-49.8%
Net Income	-$12M	-$8M	-53.0%